Table 1.
Demographic, disease-related, and radiographic characteristics of the NMOsd cohort.
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Cohort | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical | ||||||||||||
| Ethnicity/race | Hispanic | Multiethnic1 | African-Amer. | Hispanic | Hispanic | Caucasian | Hispanic | Afro-Carribian | Caucasian | Hispanic | Non-Caucasian % | 80% |
| Country of birth | Domin. Rep. | USA | USA | Equador | Columbia | USA | Peru | West Indies | Latvia | Domin. Rep | Non-US born % | 70% |
| Age at onset | 28 | 19 | 27 | 38 | 46 | 46 | 38 | 60 | 56 | 63 | Mean age onset (st. dev), yrs | 42.1 (±14.8) |
| Age at time of MRI (yrs) | 30 | 33 | 37 | 41 | 53 | 54 | 60 | 61 | 69 | 75 | Mean age at MRI (st. dev), yrs | 51.3 (±15.4) |
| Index event | TM | TM | ON | ON | ON | TM | TM | ON | TM | ON | Onset event ON % | 50% |
| Optic Neuritis | 2 | 5 | 6 | 2 | 3 | 0 | 3 | 2 | 0 | 1 | ON, median (range) | 2 (0–6) |
| Myelitis | 3 | 4 | 4 | 0 | 1 | 2 | 5 | 0 | 4 | 1 | Myelitis, median (range) | 2 (0–5) |
| Form of NMO | NMO | NMO | NMO | Recurrent ON | NMO | Recurrent TM | NMO | Recurrent ON | Recurrent TM | NMO | NMO (Mayo 2006 criteria) % | 60% |
| Visual acuity | <20/100 OS | <20/100 OU | <20/100 OU | 20/80 OD | <20/100 OS | ≤20/30 OU | <20/100 OS | <20/100 OS | ≤20/30 OU | ≤20/30 OU | Visual impaired % ≥1 eye | 70% |
| Need ambulatory assistance | Cane | Walker | Unassisted | Unassisted | Unassisted | Unassisted | Wheelchair | Unassisted | Unassisted | Unassisted | Need ambulatory assist % | 30% |
| Current NMO treatment | Mycophenolate | Mycophenolate prednisone | Rituximab, methotrexate | Azathioprine | Mycophenolate prednisone | Azathioprine | Rituximab | Azathioprine | Prior cytoxan | Azathioprine | On NMO therapy % | 90% |
| Vascular risk factors | No | No | No | No | No | HTN, HLD | HLD | HTN | No | HTN, HLD | With vascular risk factors % | 40% |
| MRI (lesion number on T2*/T2) | ||||||||||||
| Subcortical | 7 | 4 | 4 | 2 | 4 | 15 | 7 | 7 | 24 | 2 | Subcortical, mean (st dev) | 7.6 (±6.9) |
| Periventricular | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | Periventricular, mean (st dev) | 0.5 (±0.7) |
| Juxtacortical | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 6 | 0 | Juxtacortical, mean (st dev) | 0.8 (±1.9) |
| Corpus callosum | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | Corpus callos., mean (st dev) | 0.3 (±0.5) |
| “Thread-like” | 3 | 0 | 3 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | “Thread-like,” mean (st dev) | 0.8 (±1.2) |
| Perivenous | 0 | 1 | 1 | 0 | 3 | 0 | 1 | 1 | 0 | 1 | Perivenous, mean (st dev) | 0.8 (±0.9) |
|
| ||||||||||||
| Total, # | 8 | 5 | 5 | 2 | 4 | 19 | 10 | 7 | 30 | 2 | Total lesion count, mean (st dev) | 9.2 (±8.8) |
1Native American/Irish/African-American.
All lesions were <3 mm in diameter, except for 3 lesions in patient number 9 (see Table 1), which were ~5 mm in diameter. No cortical or basal ganglia lesions were seen.
HTN: hypertension; HLD: hyperlipidemia; NMO: neuromyelitis, optica; OD: right eye; OS: left eye; OU: both eyes; ON: optic neuritis; TM: transverse myelitis.